TransCode Therapeutics Future Growth
Future criteria checks 2/6
TransCode Therapeutics is forecast to grow revenue at 81.5% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 28.4% |
| Revenue growth rate | 81.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Nov 2024 |
Recent future growth updates
No updates
Recent updates
TransCode Therapeutics reports Q2 results
Aug 15TransCode files U.S. patent application for radiotherapy based cancer treatment
Jul 11We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely
Apr 01
Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation
Dec 15Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 1 | N/A | N/A | N/A | 1 |
| 12/31/2024 | 0 | N/A | N/A | N/A | 1 |
| 9/30/2024 | N/A | -15 | -16 | -16 | N/A |
| 6/30/2024 | N/A | -18 | -15 | -15 | N/A |
| 3/31/2024 | N/A | -17 | -18 | -17 | N/A |
| 12/31/2023 | N/A | -19 | -18 | -18 | N/A |
| 9/30/2023 | N/A | -20 | -16 | -16 | N/A |
| 6/30/2023 | N/A | -19 | -17 | -17 | N/A |
| 3/31/2023 | N/A | -19 | -16 | -16 | N/A |
| 12/31/2022 | N/A | -18 | -16 | -16 | N/A |
| 9/30/2022 | N/A | -15 | -14 | -13 | N/A |
| 6/30/2022 | N/A | -13 | -12 | -12 | N/A |
| 3/31/2022 | N/A | -6 | -9 | -9 | N/A |
| 12/31/2021 | N/A | -7 | -6 | -5 | N/A |
| 9/30/2021 | N/A | -5 | -4 | -4 | N/A |
| 6/30/2021 | N/A | -4 | -1 | -1 | N/A |
| 3/31/2021 | N/A | -7 | -1 | -1 | N/A |
| 12/31/2020 | N/A | -2 | 0 | 0 | N/A |
| 9/30/2020 | N/A | -2 | 0 | 0 | N/A |
| 12/31/2019 | N/A | -1 | -1 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if RNAZ's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if RNAZ's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if RNAZ's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: RNAZ's revenue (81.5% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: RNAZ's revenue (81.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RNAZ's Return on Equity is forecast to be high in 3 years time